

March 25, 2019



IMV Inc. to Present at Two Upcoming Investor Conferences

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that [IMV Chief Executive Officer Frederic Ors](#) will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019.

Details on each conference and presentation are as follows:

- **Venue:** Spring Investor Summit, being held April 1-2, 2019
- **Date of Presentation:** Monday, April 1
- **Time:** 8:30 a.m. ET
- **Location:** JW Marriott Hotel, Essex House, New York City

- Venue:** HC Wainwright Global Life Sciences Conference, being held April 7-9, 2019
- **Date:** Tuesday, April 9, 2019
 - **Time:** 10:40 a.m. BST
 - **Location:** Stratton Suite, Grosvenor House, A JW Marriott Hotel, London, UK

There will be a live webcast of both of these presentations available in the [events, presentations and webcasts section of IMV's website](#). Following the presentations, the webcasts will be archived for 90 days and a copy of the presentations will remain available in the same section of the website.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190325005122/en/>

Investor Relations:

Marc Jasmin, IMV Senior Director, Investor Relations and Communications

O: (902) 492-1819 ext : 1042

M: (514) 617-9481

E: mjasmin@imv-inc.com

Media:

Andrea Cohen, Sam Brown Inc.

T: (917) 209-7163

E: andreacohen@sambrown.com

Source: IMV Inc.